> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# State Street Holds 4.6% Of Twist Bioscience Without Seeking To Influence Control
- URL: https://www.bullished.co/state-street-holds-4-6-of-twist-bioscience-without-seeking-to-influence-control-6fdf48bc/
- Published: 2026-11-10T15:07:25.000Z
- Updated: 2026-11-10T15:07:25.000Z
- Description: The holding covers 3,017,072 shares, with Twist scheduled to report fiscal 2026 results Thursday before the market opens.
- Author: Matteo Parrino
- Tags: SEC Filings, TWST, Industry: Healthcare

State Street reported a [4.6% passive stake](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000733/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) in Twist Bioscience, which makes synthetic DNA and tools for biological research, in an SEC ownership disclosure filed Tuesday. Its 3,017,072-share holding was measured as of September 30, the same date that ended the fiscal year Twist is scheduled to report on Thursday.

## Voting Rights Without A Control Bid

State Street had [shared voting authority](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000733/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) over 2,846,126 shares and shared authority to sell or otherwise dispose of all 3,017,072 shares in its reported position. It had no sole voting authority.

State Street certified that the securities were bought and held as part of its ordinary business, rather than with a purpose or effect of changing or influencing Twist's control. The holding is therefore reported as a passive position, rather than a campaign to direct the company.

## The Business Behind The DNA

Twist uses a silicon-chip production platform to make custom genes and other DNA products. Its tools help researchers engineer biology, prepare genetic-sequencing samples and discover antibody-based medicines.

Customers include biotechnology and pharmaceutical businesses, diagnostic companies, hospitals, chemical and agricultural businesses, and academic researchers. Revenue comes from synthetic biology products, sequencing tools and antibody discovery and development services, including service and licensing fees and some milestone payments.

In fiscal 2025, Twist generated $376.6 million in revenue and served more than 3,800 customers worldwide. The company had 979 employees as of September 30, 2025.

## Thursday's Results Come Next

Twist's October 26 announcement scheduled its [fourth-quarter and full-year](https://markets.ft.com/data/announce/full?dockey=600-202610260800BIZWIRE%5FUSPRX%5F%5F%5F%5F20261026%5FBW468012-1&ref=bullished.co) fiscal 2026 results for Thursday before the market opens. The results cover the year ended September 30, 2026; management is also scheduled to discuss them and give a business update on an 8:00 a.m. Eastern Time call.

Twist had a $9.0 billion market capitalization in Tuesday trading as of 9:48 a.m. ET.

CEO and co-founder Emily M. Leproust and CFO Adam Laponis are scheduled to [address investor conferences](https://www.businesswire.com/news/home/20261109586009/en/Twist-Bioscience-to-Present-at-Upcoming-Investor-Conferences?ref=bullished.co) in London on November 17 and Coral Gables on December 1.

Learn

- [What a Reverse Termination Fee Means: Who Pays When a Merger Collapses →](https://www.bullished.co/learn/reverse-termination-fee-meaning/)  
A reverse termination fee is paid by the buyer to the target if a merger fails on agreed terms. See how it differs from a break-up fee, with live deal examples.
- [How To Read A Merger Proxy: A Checklist For Shareholders Facing A Vote →](https://www.bullished.co/learn/merger-proxy-statement-how-to-read/)  
Facing a merger vote? Read the proxy in this order: price and payment, vote date and threshold, board background, synergy claims, then closing conditions.

### Sources

- [SCHEDULE 13G — STATE STREET CORPORATION re: TWIST BIOSCIENCE CORP (TWST)](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000733/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR
- [Twist Bioscience to Report Fiscal 2026 Fourth Quarter and Full Year Financial Results on Thursday, November 12, 2026 – Company Announcement - FT.com](https://markets.ft.com/data/announce/full?dockey=600-202610260800BIZWIRE%5FUSPRX%5F%5F%5F%5F20261026%5FBW468012-1&ref=bullished.co) — Financial Times
- [Biotechnology Stock Performance - Yahoo Finance](https://finance.yahoo.com/sectors/healthcare/biotechnology/?ref=bullished.co) — Yahoo Finance
- [Twist Bioscience to Present at Upcoming Investor Conferences](https://www.businesswire.com/news/home/20261109586009/en/Twist-Bioscience-to-Present-at-Upcoming-Investor-Conferences?ref=bullished.co) — businesswire.com